Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease

被引：181

作者：

Hardy, Timothy ^{[1
,2
]}

Zeybel, Mujdat ^{[3
]}

Day, Christopher P. ^{[1
]}

Dipper, Christian ^{[2
]}

Masson, Steven ^{[2
]}

McPherson, Stuart ^{[2
]}

Henderson, Elsbeth ^{[2
]}

Tiniakos, Dina ^{[1
,4
]}

White, Steve ^{[5
]}

French, Jeremy ^{[5
]}

Mann, Derek A. ^{[1
]}

Anstee, Quentin M. ^{[1
,2
]}

Mann, Jelena ^{[1
]}

机构：

[1] Newcastle Univ, Inst Cellular Med, Fibrosis Labs, 4th Floor,William Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

[2] Newcastle Tyne Hosp NHS Fdn Trust, Dept Gastroenterol & Hepatol, Newcastle Upon Tyne, Tyne & Wear, England

[3] Koc Univ, Sch Med, Istanbul, Turkey

[4] Newcastle Tyne Hosp NHS Fdn Trust, Dept Cellular Pathol, Newcastle Upon Tyne, Tyne & Wear, England

[5] Newcastle Tyne Hosp NHS Fdn Trust, Dept Hepatobiliary Surg, Newcastle Upon Tyne, Tyne & Wear, England

来源：

GUT | 2017年 / 66卷 / 07期

基金：

欧盟地平线“2020”; 英国医学研究理事会;

关键词：

HEPATIC STELLATE CELLS; FOLLOW-UP; MYOFIBROBLAST TRANSDIFFERENTIATION; NAFLD; PROGRESSION; RECEPTOR; STEATOHEPATITIS; REGENERATION; ACTIVATION; SYSTEM;

D O I：

10.1136/gutjnl-2016-311526

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Objective Liver biopsy is currently the most reliable way of evaluating liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Its inherent risks limit its widespread use. Differential liver DNA methylation of peroxisome proliferator-activated receptor gamma (PPAR.) gene promoter has recently been shown to stratify patients in terms of fibrosis severity but requires access to liver tissue. The aim of this study was to assess whether DNA methylation of circulating DNA could be detected in human plasma and potentially used to stratify liver fibrosis severity in patients with NAFLD. Design Patients with biopsy-proven NAFLD and age-matched controls were recruited from the liver and gastroenterology clinics at the Newcastle upon Tyne Hospitals NHS Foundation Trust. Plasma cell-free circulating DNA methylation of PPAR. was quantitatively assessed by pyrosequencing. Liver DNA methylation was quantitatively assessed by pyrosequencing NAFLD explant tissue, subjected to laser capture microdissection (LCM). Patients with alcoholic liver disease (ALD) were also subjected to plasma DNA and LCM pyrosequencing. Results 26 patients with biopsy-proven NAFLD were included. Quantitative plasma DNA methylation of PPAR. stratified patients into mild (Kleiner 1-2) and severe (Kleiner 3-4) fibrosis (CpG1: 63% vs 86%, p<0.05; CpG2: 51% vs 65% p>0.05). Hypermethylation at the PPAR. promoter of plasma DNA correlated with changes in hepatocellular rather than myofibroblast DNA methylation. Similar results were demonstrated in patients with ALD cirrhosis. Conclusions Differential DNA methylation at the PPAR. promoter can be detected within the pool of cell-free DNA of human plasma. With further validation, plasma DNA methylation of PPAR. could potentially be used to non-invasively stratify liver fibrosis severity in patients with NAFLD. Plasma DNA methylation signatures reflect the molecular pathology associated with fibrotic liver disease.

引用

页码：1321 / 1328

页数：8

共 35 条

[1] The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].